Technology
We empower oncologists to improve the treatment of cancer by unlocking a drug’s full potential through sustained, high-dose treatment at the tumor site.
Leveraging decades of material science, pharmacology, and cancer biology, PanTher’s technology has emerged as the solution many have been looking for in order to continuously administer high doses of potent drugs at the site of a tumor.
How we develop long-lasting,
HIGH-DOSE cancer TREATMENTS
ONE
Engineer optimal drug dose and duration of treatmentPanTher’s drug products are designed to contain the desired chemotherapeutic agent for each specific indiction
TWO
Design for minimally invasive placementTHREE
Clinically assess surgical feasibility, safety, and therapeutic benefitPanTher’s Long-Lasting, Exclusively Local, Drug Development Platform
Transforming a Poorly Tolerated Drug into a Highly Effective Treatment
Potent drugs can now be administered exclusively to the site of a tumor. This enables uninterrupted administration of >100 fold higher concentrations of drug to be delivered to the tumor site over weeks or months.
Currently available potent drugs often have limited effectiveness due to dose-limiting systemic toxicities, with typically less than 1% reaching the tumor and over 99% of drug reaching off-target tissues.
Sagittari™ Platform
Our platform combines six interactive modules for optimal therapeutic design.
Sagittari™
Indications
We can target a broad range of localized cancer indications (e.g., pancreatic, colon, lung)
Route of Administration
We can adapt the route of administration to meet the needs of tumor location (e.g., minimally invasive, open surgery)
Dosage Form
There are a number of dosage forms that we can use (e.g., patch, tubular) to ensure we can reach the tumor using SOC procedures for a given indication
Therapeutic
Although currently focused on developing improved chemotherapy treatments, we can apply our technology to different drug modalities (e.g., mRNA, proteins)
Dose
We can tailor the dose level of a given drug to each specific application
Timing
We can control when dosing starts and its duration
PanTher CEO, Laura Indolfi: TED Talk on the Promise of PanTher's Technology
